close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Roche Holding AG
Search

Roche Holding AG

Suletud

SektorTervishoid

300.4 -1.05

Hinna uuendus 14. nov 2025, 16:16 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

295.2

Max

303.8

Põhinäitajad

By Trading Economics

Sissetulek

1.7B

3.7B

Müük

-15B

16B

P/E

Sektori keskmine

25.106

105.69

Dividenditootlus

3.34

Kasumimarginaal

23.266

Töötajad

103,249

EBITDA

547M

6.5B

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.34%

2.37%

Turustatistika

By TradingEconomics

Turukapital

5.5B

211B

Eelmine avamishind

301.45

Eelmine sulgemishind

300.4

Uudiste sentiment

By Acuity

9%

91%

8 / 374 Pingereas Healthcare

Roche Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2025, 09:32 UTC

Tulu

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

DJ

Loe

23. okt 2025, 05:54 UTC

Tulu

Roche Raises Full-Year Earnings Outlook

DJ

Loe

1. okt 2025, 08:54 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

DJ

Loe

18. sept 2025, 14:01 UTC

Omandamised, ülevõtmised, äriostud

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

DJ

Loe

18. sept 2025, 10:05 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

89bio Shares Soar Premarket on Takeover by Roche

DJ

Loe

18. sept 2025, 10:04 UTC

Omandamised, ülevõtmised, äriostud

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

DJ

Loe

18. sept 2025, 05:37 UTC

Omandamised, ülevõtmised, äriostud

Roche to Buy 89bio for Up to $3.5 Billion

DJ

Loe

10. nov 2025, 12:16 UTC

Market Talk
Tulu

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

DJ

Loe

23. okt 2025, 09:19 UTC

Market Talk
Tulu

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

DJ

Loe

23. okt 2025, 09:11 UTC

Market Talk
Tulu

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

DJ

Loe

23. okt 2025, 05:09 UTC

Tulu

Roche 3Q Sales Up 6% At CER

DJ

Loe

23. okt 2025, 05:07 UTC

Tulu

Roche 3Q Sales CHF14.92B

DJ

Loe

23. okt 2025, 05:07 UTC

Tulu

Analysts Had Seen 3Q Sales At CHF15.17B

DJ

Loe

23. okt 2025, 05:07 UTC

Tulu

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

DJ

Loe

23. okt 2025, 05:05 UTC

Tulu

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

DJ

Loe

23. okt 2025, 05:04 UTC

Tulu

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

DJ

Loe

23. okt 2025, 05:02 UTC

Tulu

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

DJ

Loe

23. okt 2025, 05:02 UTC

Tulu

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

DJ

Loe

23. okt 2025, 05:02 UTC

Tulu

Roche 9-Mos CH45.9B

DJ

Loe

23. okt 2025, 05:01 UTC

Tulu

Roche Raises 2025 View

DJ

Loe

1. okt 2025, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

DJ

Loe

1. okt 2025, 09:05 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

DJ

Loe

18. sept 2025, 14:12 UTC

Omandamised, ülevõtmised, äriostud

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

DJ

Loe

18. sept 2025, 07:37 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

DJ

Loe

18. sept 2025, 05:09 UTC

Omandamised, ülevõtmised, äriostud

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

DJ

Loe

18. sept 2025, 05:06 UTC

Omandamised, ülevõtmised, äriostud

Roche: Deal Is Expected to Close in 4Q

DJ

Loe

18. sept 2025, 05:06 UTC

Omandamised, ülevõtmised, äriostud

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

DJ

Loe

18. sept 2025, 05:05 UTC

Omandamised, ülevõtmised, äriostud

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

DJ

Loe

18. sept 2025, 05:05 UTC

Omandamised, ülevõtmised, äriostud

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

DJ

Loe

18. sept 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

DJ

Loe

Roche Holding AG Prognoos

Sentiment

By Acuity

8 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat